Marked improvement with sildenafil in a patient with primary pulmonary hypertension unresponsive to epoprostenol

Internal Medicine

Volumn 43, Issue 10, 2004, Pages 945-950

  Kataoka, Masaharu ^a   Satoh, Toru ^a   Manabe, Tomohiro ^a   Anzai, Toshihisa ^a   Yoshikawa, Tsutomu ^a   Mitamura, Hideo ^a   Ogawa, Satoshi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Epoprostenol; Primary pulmonary hypertension; Right heart failure; Sildenafil

Indexed keywords

DOBUTAMINE; FUROSEMIDE; NIFEDIPINE; OXYGEN; PROSTACYCLIN; SILDENAFIL; SPIRONOLACTONE; WARFARIN;

ADULT; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CLINICAL FEATURE; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG INFUSION; DYSPNEA; ECHOCARDIOGRAPHY; FEMALE; HEART DISEASE; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; HYPOTENSION; LABORATORY TEST; LIVER DYSFUNCTION; LUNG ARTERY PRESSURE; LUNG DISEASE; LUNG EMBOLISM; LUNG FUNCTION TEST; LUNG SCINTISCANNING; OXYGEN THERAPY; PULMONARY HYPERTENSION; PULMONARY VALVE INSUFFICIENCY; SYSTEMIC DISEASE; THORAX RADIOGRAPHY; TREATMENT FAILURE; TREATMENT OUTCOME; TRICUSPID VALVE REGURGITATION; VASCULAR DISEASE; VISUAL DISORDER;

ANTIHYPERTENSIVE AGENTS; ELECTROCARDIOGRAPHY; EPOPROSTENOL; FEMALE; HUMANS; HYPERTENSION, PULMONARY; LUNG; MIDDLE AGED; PIPERAZINES; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 8844256580     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.945     Document Type: Article

References (14)

1. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: Results from a National Prospective Registry. Ann Intern Med 115: 343-349, 1991.
2. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334: 296-302, 1996.
3. Bennett LE, Keck BM, Hertz MI, Trulock EP, Taylor DO. Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT international registry for thoracic organ transplantation. Clin Transpl 2001: 25-40, 2001.
4. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation 99: 168-177, 1999.
5. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 327: 76-81, 1992.
6. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 70: 580-587, 1984.
7. Jones DK, Higgenbottam TW, Wallwork J. Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin). Br Heart J 57: 270-278, 1987.
8. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338: 273-277, 1998.
9. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 99: 1858-1865, 1999.
10. Stiebellehner L, Petkov V, Vonbank K, et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 123: 1293-1295, 2003.
11. Weimann J, Ullrich R, Hromi J, et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 92: 1702-1712, 2000.
12. Michelakis ED, Tymchak W, Noga M, et al. Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation 108: 2066-2069, 2003.
13. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 84: E4, 2000.
14. Ghofrani HA, Wiedemann R, Rose F, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136: 515-522, 2002.